Sam Brusco, Associate Editor06.02.21
Medical imaging AI specialist Avicenna.AI gained certification in the U.S. and EU for CINA CHEST, an AI solution that leverages deep learning algorithms for emergency triage of deadly vascular conditions.
In addition to securing a CE mark, CINA CHEST received 510(k) clearance from the FDA for its automatic detection and triage capabilities for pulmonary embolism (PE) and aortic dissection (AD) from CT scans.
Pulmonary embolism is the blockage of an artery in the lungs and is one of the major causes of death, morbidity, and hospitalization worldwide. It is difficult to diagnose PE as it manifests in diverse ways and can be mimicked by a range of other conditions. CINA CHEST provides rapid automatic PE detection on CT chest angiography, providing clinicians with accurate and rapid real-time alerts on the disease.
Aortic dissection is a tear in the inner layer of the aorta, allowing blood to flow between the layers. Although relatively rare, AD has a high mortality rate and is often not diagnosed when it first appears. Patients who receive the appropriate treatment in a timely manner have a high survival rate, so the importance of a quick and accurate diagnosis is critical. CINA CHEST identifies acute AD cases that require urgent intervention, providing accurate, real-time alerts on thoraco-abdominal CT angiography.
CINA CHEST is part of Avicenna's CINA family of AI tools that support the treatment of emergencies, including CINA HEAD, its FDA-cleared and CE-marked solution that supports the detection and triage of stroke and neurovascular emergencies.
"At Avicenna, we specialize in the development of AI algorithms that can identify acute abnormalities, and CINA CHEST is the latest application we've developed to enhance emergency room radiology," Cyril Di Grandi, co-founder and CEO of Avicenna.AI told the press. "Our PE and AD triage tools are the third and fourth algorithms we've released in less than 12 months, demonstrating our ambition to create AI applications that support detection and triage of emergencies throughout the entire body."
In addition to securing a CE mark, CINA CHEST received 510(k) clearance from the FDA for its automatic detection and triage capabilities for pulmonary embolism (PE) and aortic dissection (AD) from CT scans.
Pulmonary embolism is the blockage of an artery in the lungs and is one of the major causes of death, morbidity, and hospitalization worldwide. It is difficult to diagnose PE as it manifests in diverse ways and can be mimicked by a range of other conditions. CINA CHEST provides rapid automatic PE detection on CT chest angiography, providing clinicians with accurate and rapid real-time alerts on the disease.
Aortic dissection is a tear in the inner layer of the aorta, allowing blood to flow between the layers. Although relatively rare, AD has a high mortality rate and is often not diagnosed when it first appears. Patients who receive the appropriate treatment in a timely manner have a high survival rate, so the importance of a quick and accurate diagnosis is critical. CINA CHEST identifies acute AD cases that require urgent intervention, providing accurate, real-time alerts on thoraco-abdominal CT angiography.
CINA CHEST is part of Avicenna's CINA family of AI tools that support the treatment of emergencies, including CINA HEAD, its FDA-cleared and CE-marked solution that supports the detection and triage of stroke and neurovascular emergencies.
"At Avicenna, we specialize in the development of AI algorithms that can identify acute abnormalities, and CINA CHEST is the latest application we've developed to enhance emergency room radiology," Cyril Di Grandi, co-founder and CEO of Avicenna.AI told the press. "Our PE and AD triage tools are the third and fourth algorithms we've released in less than 12 months, demonstrating our ambition to create AI applications that support detection and triage of emergencies throughout the entire body."
